OTC · Health care

Protagenic Therapeutics, Inc. (PTIX)

In fiscal 2026 capital spending exceeded operating cash flow by $2.8M. At June 30, 2026 it held $566K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 19, 2026.

Watch PTIX in 60 seconds

Price

$0.78

-4.41% on the day · September 28, 2026

52-week range $0.13 to $4.42

Market cap

$1.4M

P/E

1.3

on FY2026 diluted EPS

What Protagenic Therapeutics, Inc. does

Protagenic Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker PTIX.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2026	$0	-$4.5M	$1.4M	$0.59	-$2.8M
2026	$0	-$2.6M	-$3.6M	-$0.67	n/a
2024	$0	-$5.7M	-$5.5M	-$1.13	n/a
2023	$0	-$4.5M	-$5M	-$1.15	-$3.9M
2022	$0	-$3.6M	-$3.6M	-$0.82	-$2M
2021	$0	-$4.1M	-$4.5M	-$0.31	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around December 23, 2026.

Estimated from its filing rhythm: about 131 days after its last report of August 14, 2026, its usual gap. Not a date the company has announced. See the report calendar

Latest SEC filings

What Protagenic Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 20, 2026
Investor disclosure 8-K
August 19, 2026
Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.53 versus -$1.37.
August 14, 2026
Late quarterly report notice NT 10-Q
August 14, 2026
Annual report 10-K · period to March 31, 2026Diluted EPS $0.59 versus -$0.67.
June 30, 2026
Late annual report notice NT 10-K
April 7, 2026
Executive or director change 8-K
March 9, 2026
Quarterly report 10-Q · period to December 31, 2025Diluted EPS $1.14 versus -$0.16.
March 3, 2026
Executive or director change 8-K
February 24, 2026
Acquisition or sale completed 8-K
February 18, 2026
Late quarterly report notice NT 10-Q

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 24, 2026. Insider transactions on SEC

Insider trades

What the people running Protagenic Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders bought $30.7K worth of shares on the open market in the last 90 days and sold none.

Bought (open market)

$30.7K

last 90 days

Sold

last 90 days

Net bought

73,530

$30.7K

Date	Insider	What	Shares	Price	Value	Filing
August 21, 2026	Armen Garo HEXEC. CHAIR & PRINCIPAL OFF, Director	Bought	20,000	$0.65	$13K	Form 4
August 20, 2026	Armen Garo HEXEC. CHAIR & PRINCIPAL OFF, Director	Bought	16,634	$0.59	$9.8K	Form 4
August 19, 2026	Armen Garo HEXEC. CHAIR & PRINCIPAL OFF, Director	Bought	2,700	$0.35	$945	Form 4
August 11, 2026	Armen Garo HEXEC. CHAIR & PRINCIPAL OFF, Director	Bought	2,220	$0.32	$710.4	Form 4
August 6, 2026	Armen Garo HEXEC. CHAIR & PRINCIPAL OFF, Director	Bought	685	$0.22	$150.7	Form 4
August 5, 2026	Armen Garo HEXEC. CHAIR & PRINCIPAL OFF, Director	Bought	5,000	$0.26	$1.3K	Form 4
July 30, 2026	Armen Garo HEXEC. CHAIR & PRINCIPAL OFF., Director	Bought	26,291	$0.18	$4.8K	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns PTIX

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

No holder of 5% or more has filed about this company in that window.

Latest filings below 5%: Bigger Capital Fund L P 0% (August 25, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

1 insiders reported holding 73,533 shares in total, about $57.4K at the last price.

Holder	Shares	As of
Armen Garo HEXEC. CHAIR & PRINCIPAL OFF, Director	73,533	August 21, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about PTIX

What does Protagenic Therapeutics, Inc. do?

Protagenic Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker PTIX.

Is Protagenic Therapeutics, Inc. profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $5.5M.

When did Protagenic Therapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 19, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from August 24, 2026.

Similar companies

TAK

Takeda Pharmaceutical Co Ltd

Compare PTIX with

Compare PTIX with any company

Follow PTIX

Get an email when Protagenic Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow PTIX: get an email when it files

Where the numbers come from

Financial figures are the values Protagenic Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.